Biotechnology

Maia Fertility lands key VC funding to prove its Ferizyme™ platform in cattle, paving a strategic, data-driven path toward human reproductive medicine.

Clinical research leader Novotech offers a strategic roadmap for biotech and pharma, aiming to de-risk and accelerate the complex world of autoimmune drug development.

By assembling a 'dream team' of scientific advisors, INmune Bio isn't just advancing a drug; it's fortifying the very structure of cell therapy development.

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

Basking Biosciences' BB-031 targets a key clotting protein, dissolving clots hours later than current drugs. With a unique reversal agent, it could transform stroke care.

AB2 Bio's partnership with Nippon Shinyaku for Tadekinig alfa signals a new era for ultra-rare pediatric care and highlights a savvy biotech financing strategy.

With FDA clearance for IKS04, Iksuda Therapeutics unveils a novel co-dosing strategy to deliver a potent payload past notorious tumor barriers.

Lōkahi Therapeutics aims to turn 15 injections into one for its pain drug LT-100, a move that could transform patient care and unlock major commercial value.

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

Skincare brand Valitic hit 2M customers, but the real story is how its e-commerce success provides the cash flow for parent Innocan Pharma's biotech ambitions.

Octapharma's $1.5 billion Rock Hill facility promises 1,500 high-paying jobs. But beyond the local boom, it signals a critical shift in securing America's medical supply chain.

A small logistics firm with big ambitions breaks ground in rural Alabama, promising a $500M biomanufacturing hub to help secure America's drug supply.

A $3.5M fundraiser is just the start. Northwell's Feinstein Institutes are turning donations into FDA-approved nerve implants that are changing medicine.

Clene Inc. heads to the Canaccord Growth Conference with promising ALS data and a clear regulatory path, but faces a critical test of investor confidence.

As RenovoRx preps its Q2 update, it's proving its mettle on two fronts: impressive sales of its RenovoCath device and a critical milestone in its pancreatic cancer trial.

The FNIH is launching a landmark study using AI and biomarkers to redefine depression, moving beyond guesswork toward precision care for millions.

As Akebia Therapeutics preps its Q2 report, all eyes are on Vafseo's uptake, a declining Auryxia, and a costly R&D push into rare kidney diseases.

With a novel drug targeting an unaddressed cause of glaucoma, Qlaris Bio adds a seasoned expert to its board, signaling a pivotal push toward market entry.

Processa Pharmaceuticals acquires Vidya Therapeutics and its key asset, VT-7208, backed by a $200M financing that radically overhauls the company's strategy.

A new study on umbilical cord allografts offers hope for chronic neck pain, but a closer look reveals the complex scientific and regulatory networks that will define its future.